Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Portola Pharmaceuticals (NASDAQ:PTLA) Downgraded to “Sell” at BidaskClub

researchsnappy by researchsnappy
December 29, 2019
in Investment Research
0
Portola Pharmaceuticals Inc (NASDAQ:PTLA) Receives $38.75 Average Target Price from Analysts
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Portola Pharmaceuticals Inc logoBidaskClub lowered shares of Portola Pharmaceuticals (NASDAQ:PTLA) from a hold rating to a sell rating in a report released on Wednesday, December 4th, BidAskClub reports.

A number of other research analysts also recently weighed in on PTLA. Cowen reissued a buy rating and set a $45.00 target price on shares of Portola Pharmaceuticals in a research report on Tuesday, November 5th. Goldman Sachs Group started coverage on shares of Portola Pharmaceuticals in a research report on Friday, November 8th. They set a neutral rating and a $35.00 target price for the company. Morgan Stanley initiated coverage on shares of Portola Pharmaceuticals in a research report on Thursday, September 5th. They set a hold rating and a $37.00 target price for the company. Zacks Investment Research raised shares of Portola Pharmaceuticals from a hold rating to a buy rating and set a $30.00 price objective for the company in a report on Wednesday, October 9th. Finally, ValuEngine downgraded shares of Portola Pharmaceuticals from a sell rating to a strong sell rating in a report on Monday, October 21st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Portola Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $38.75.

Shares of Portola Pharmaceuticals stock traded down $0.33 on Wednesday, reaching $25.06. 691,800 shares of the company traded hands, compared to its average volume of 847,501. Portola Pharmaceuticals has a 52 week low of $16.08 and a 52 week high of $37.95. The company has a 50 day moving average of $27.54 and a 200 day moving average of $27.77. The firm has a market capitalization of $1.98 billion, a PE ratio of -5.00 and a beta of 2.06. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.88 and a quick ratio of 5.85.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.14. Portola Pharmaceuticals had a negative net margin of 275.13% and a negative return on equity of 282.04%. The firm had revenue of $36.80 million during the quarter, compared to the consensus estimate of $34.64 million. During the same period in the prior year, the firm earned ($1.08) EPS. The company’s revenue was up 159.2% compared to the same quarter last year. As a group, analysts anticipate that Portola Pharmaceuticals will post -3.49 earnings per share for the current year.

In other news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the sale, the director now owns 18,194 shares in the company, valued at approximately $545,820. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of PTLA. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Portola Pharmaceuticals by 45.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 18,310 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 5,700 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Portola Pharmaceuticals by 16.6% during the 2nd quarter. Fisher Asset Management LLC now owns 100,722 shares of the biopharmaceutical company’s stock valued at $2,733,000 after buying an additional 14,338 shares in the last quarter. First Trust Advisors LP purchased a new stake in shares of Portola Pharmaceuticals during the 2nd quarter valued at $3,110,000. Aperio Group LLC purchased a new stake in shares of Portola Pharmaceuticals during the 2nd quarter valued at $152,000. Finally, J. L. Bainbridge & Co. Inc. purchased a new stake in shares of Portola Pharmaceuticals during the 2nd quarter valued at $202,000.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Featured Story: Float

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)



Receive News & Ratings for Portola Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Portola Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Why you shouldn’t wash your T-shirt after one wear

Next Post

Automotive Hydraulic Steering Market Price Analysis 2019-2026 – Market Reports Observer

Next Post
Dynamics, Segments, Size and Demand, 2019-2025 – Crypto Journal

Automotive Hydraulic Steering Market Price Analysis 2019-2026 – Market Reports Observer

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com